Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
March 11, 2025 08:00 ET
|
Exagen Inc.
Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of...
Exagen Inc. to Participate in Upcoming Investor Conferences
February 04, 2025 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming...
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
January 12, 2025 12:00 ET
|
Exagen Inc.
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following...
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024 08:00 ET
|
Exagen Inc.
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD,...
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
October 29, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024,...
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
October 21, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College...
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
September 04, 2024 16:05 ET
|
Exagen Inc.
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global...
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
August 05, 2024 08:00 ET
|
Exagen Inc.
CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30,...
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
July 22, 2024 09:00 ET
|
Exagen Inc.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before...